Want to see BCDA full AI Analyst Report?
BCDA Stock Chart & Stats
$1.18
-$0.06(-2.59%)
At close: 4:00 PM EST
$1.18
-$0.06(-2.59%)
Day’s Range― - ―
52-Week Range$0.78 - $2.42
Previous CloseN/A
Volume12.78K
Average Volume (3M)6.17M
Market Cap
$12.29M
Enterprise Value$12.54
Total Cash (Recent Filing)$951.00K
Total Debt (Recent Filing)$412.00K
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Aug 12, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding14,884,328
10 Day Avg. Volume502,917
30 Day Avg. Volume6,172,481
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.31
Price to Sales (P/S)0.00
P/FCF Ratio-1.12
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$15.50Price Target Upside1213.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory PathwaysClear, favorable regulatory engagement with both FDA and Japan’s PMDA establishes defined approval routes. A PMA pathway in the U.S. and PMDA willingness to accept existing data materially reduce regulatory uncertainty and create a realistic, actionable roadmap to market over the next 12–24 months.
Proprietary Delivery/IPPatented Heart3D imaging and the Helix delivery platform create durable competitive moats by integrating device, imaging and delivery capabilities. These proprietary assets support differentiation, potential partnership licensing, and multiple commercialization routes beyond a single therapy, strengthening long-term strategic optionality.
Clinical EvidenceStatistically significant blinded echocardiography outcomes and durable clinical improvements in refractory ischemia provide persistent clinical credibility. Robust efficacy and safety signals underlie regulatory submissions, payer discussions, and physician adoption — foundational for commercial uptake if confirmatory trials succeed.
Bears Say
Weak FinancialsZero meaningful revenue, sustained operating losses and negative TTM equity undermine financial resilience. This structural weakness limits the company’s ability to self-fund development, increases dependence on external capital, and elevates dilution risk over the next several quarters absent durable revenue or partner funding.
Cash Runway RiskSub‑one‑million dollars of cash versus multi‑million quarterly burn creates a material near‑term financing necessity. Reliance on periodic equity raises or transactions to bridge key regulatory milestones increases execution and dilution risk and can disrupt trial timelines and partner negotiations.
Pivotal Trial ExecutionU.S. approval hinges on completing a large, resource‑intensive pivotal trial. Slow center activation and the need for rapid enrollment create durable operational risk: delays or underpowered results would postpone commercialization, increase cash needs, and impair the company’s ability to capture projected market opportunity.
BioCardia News
BCDA FAQ
What was Biocardia’s price range in the past 12 months?
Biocardia lowest stock price was $0.78 and its highest was $2.42 in the past 12 months.
What is Biocardia’s market cap?
Biocardia’s market cap is $12.29M.
When is Biocardia’s upcoming earnings report date?
Biocardia’s upcoming earnings report date is Aug 12, 2026 which is in 24 days.
How were Biocardia’s earnings last quarter?
Biocardia released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.165 by -$0.045.
Is Biocardia overvalued?
According to Wall Street analysts Biocardia’s price is currently Undervalued.
Does Biocardia pay dividends?
Biocardia does not currently pay dividends.
What is Biocardia’s EPS estimate?
Biocardia’s EPS estimate is -0.18.
How many shares outstanding does Biocardia have?
Biocardia has 14,884,328 shares outstanding.
What happened to Biocardia’s price movement after its last earnings report?
Biocardia reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.165. Following the earnings report the stock price went down -7.339%.
Which hedge fund is a major shareholder of Biocardia?
Currently, no hedge funds are holding shares in BCDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocardia
BioCardia, Inc. is a pioneering clinical-stage company dedicated to regenerative medicine, focusing on the development of advanced cellular and cell-derived therapies for a range of cardiac and respiratory ailments. Central to its pipeline is the CardiAMP Cell Therapy System, designed to address heart failure and chronic myocardial ischemia. Additionally, BioCardia is advancing an allogeneic cell therapy program, also targeting cardiac and pulmonary conditions. The company is further exploring a specific allogeneic cell therapeutic platform. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. Beyond its therapeutic candidates, BioCardia also provides innovative delivery solutions. These include the Helix biotherapeutic delivery system, engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle, and a line of Morph deflectable guides and sheaths. BioCardia maintains its headquarters in Sunnyvale, California.
BCDA Stock 12 Month Forecast
Average Price Target
$15.50
▲(1213.56% Upside)
Technical Analysis
Ownership Overview
14.61% Insiders
1.26% Mutual Funds
<0.01% Other Institutional Investors
83.29% Public Companies and
Individual Investors